Protein-kinase inhibitors: A new treatment pathway for autoimmune and inflammatory diseases?
Although advances in biological medicine have seen significant progress in the treatment of autoimmune and inflammatory disease, many patients do not experience a satisfactory response. Hence, there are two challenges facing the medical research community. The first is to continue development in the field of existing biological therapies, such as monoclonal antibodies. The second is to open new frontiers of research and explore treatment alternatives for non-responders to other therapies. Attention has increasingly turned to the therapeutic potential of small molecule weight kinase inhibitors (SMKIs), currently used extensively in oncology and haematology. Initial research into the therapeutic value of SMKIs for autoimmune and inflammatory diseases has been encouraging. SMKIs are taken orally, which reduces cost for the health provider, and could increase compliance for the patient. This is why research is now focusing increasingly on SMKIs as a new generation line of treatment in these diseases. Tofacitinib, an inhibitor of Janus-kinase, is currently the only drug approved for the treatment of rheumatoid arthritis by FDA. However, much more needs to be done to understand the intracellular signalling pathways and how these might affect disease progression before solid conclusions can be drawn.
Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, España.
Diana
D
Hernández-Flórez
Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, España. Electronic address: lvalor.hgugm@salud.madrid.org.
Lara
L
Valor
D000284:Administration, Oral; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000378:metabolism; D010880:Piperidines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D015398:Signal Transduction; D016896:Treatment Outcome
D018501:Antirheumatic Agents; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; C479163:tofacitinib
Autoimmunity; Autoinmunidad; Inflamación; Inflammation; Inhibidores de las tirosinas-cinasas; Intracellular signalling; Kinase inhibitors; Protein-kinase; Proteínas-cinasas; Tirosinas-cinasas; Tofacitinib; Tyrosine-kinase; Vías de señalización intracelular